Cannabis Law Report

JANUARY 12, 2022

“This is a landmark event for Gb Sciences,” said Chairman and CEO John Poss. “We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinical trials.” ” . . In addition, Gb Sciences has 12 U.S. 31, 2021.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

The Joint Blog

APRIL 17, 2020

This study summarizes potential adverse drug events related to THC when combined with other medications Medicinal Use of Marijuana Cannabis has been used widely across North America in various state or provincial medical marijuana programs. However, in some cases, the risks may outweigh even the proven benefits.

Events 48

Events THC Chronic Pain Sleep 48

Puff Puff Post

JULY 8, 2019

When she is not training for running events, Dr. Zeiger works as a cannabis epidemiologist. Nearly half of the athletes reported either acute or chronic pain. Cannabis may have a role in the daily health regimen for active athletes suffering from pain, anxiety, and insomnia.

Chronic Pain 109

Chronic Pain Research and Development Clinical Trials THC 109

Puff Puff Post

JULY 8, 2019

When she is not training for running events, Dr. Zeiger works as a cannabis epidemiologist. Nearly half of the athletes reported either acute or chronic pain. Cannabis may have a role in the daily health regimen for active athletes suffering from pain, anxiety, and insomnia.

Chronic Pain 108

Chronic Pain Research and Development Clinical Trials THC 108

Cannabis Law Report

JUNE 8, 2021

This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. Investor Relations Contact: Hayden IR. Brett Maas. 646-536-7331. Email: brett@haydenir.com.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

Cannabis Law Report

OCTOBER 17, 2019

Tree of Knowledge will be introducing chronic pain management protocols and research into the Caribbean market. The introduction of these protocols will take the form of clinical trials and research that will include the usage of specific strains of cannabis that aid in chronic pain and cancer treatments.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain CBD 40

Cannabis Law Report

AUGUST 24, 2021

The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Veriheal

MAY 3, 2022

The team sought to answer the following: “What are the risks and benefits of obtaining a medical marijuana card for adults who seek medical marijuana for pain, insomnia and anxiety or depressive symptoms?”—a Clinical Trial Sample Size. a necessary question to address as medical marijuana becomes more accessible.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Cannabis Law Report

OCTOBER 19, 2021

The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. About MyMD Pharmaceuticals, Inc. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Law Report

OCTOBER 5, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression. Investor: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

DECEMBER 1, 2021

The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. About MyMD Pharmaceuticals, Inc. Robert Schatz.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

AUGUST 26, 2022

In addition, while many people rely on northern lights strains and other Indica strains of cannabis to tackle depression, the use of CBD has been proven to extend to chronic pain relief. Apart from this, various clinical trials are done for multiple conditions. What are the common triggers of it?

Epilepsy 52

Epilepsy Treatment CBD Sleep 52

Cannabis Law Report

SEPTEMBER 22, 2021

Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

SpeedWeed

AUGUST 4, 2021

After watching my brother self-medicate for his chronic pain for decades, I didn’t understand how cannabis was important to him as a medicine. I always thought he used his chronic pain as an “excuse” to self-administer what I thought was a toxic drug. . in 2014, I watched my brother walk into a cannabis clinic.

Chronic Pain 52

Chronic Pain Research and Development Medicine Supply Chain 52

Veriheal

JULY 12, 2021

According to the American Psychiatric Association , PTSD is a “psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as natural disaster, as a serious accident, a terrorist act, war/combat or rape or who have been threatened with death, sexual violence or serious injury”.

Treatment 104

Treatment Sleep Clinical Trials Data 104

Cannabis Law Report

OCTOBER 26, 2021

MyMD plans to advance MYMD-1 in the clinic with two simultaneous Phase 2 trials beginning in the current quarter, one for delaying aging and prolonging healthy lifespan, and the second for COVID-19-associated depression and cytokine elevation. Dr. Chapman Bio. Chapman has operated Chapman Pharmaceutical Consulting, Inc., 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JULY 4, 2019

The programme aims to investigate mechanisms of action of cannabis-based medicinal products related to several clinical applications including pain and cancer, as well as characterise cannabis-based medicinal products in disease models with particular focus of chronic pain, spasticity and cancer.

Cannabinoids 40

Cannabinoids Clinical Trials Chronic Pain Medicine 40

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 23, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression. MyMD Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

JANUARY 5, 2022

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression. 2 Goates et al. 3 Koon Yee-Lee et al. 4 [link].

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

The Joint Blog

JUNE 2, 2020

The study, titled Pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial , was first published by NORML. “The 1mg dose showed a significant pain decrease compared to the placebo. .

Chronic Pain 58

Chronic Pain Clinical Trials Marijuana Safety 58

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. For example, most statin drugs can cause memory issues, muscle pain, fatigue and muscle weakness.

CBD 98

CBD THC Conditions Medicine 98

Cannabis Law Report

DECEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., Christopher M. Chipman, CPA. Chief Financial Officer. cchipman@virpaxpharma.com 610-727-4597.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

The Cannigma

DECEMBER 12, 2022

Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. Current clinical trials are underway using a synthetic nasal spray of 5-MeO-DMT in patients with major depressive disorder. As such, there have been numerous clinical trials using ketamine. This stage lasts for 8 to 20 hours.

History 119

History Microdosing Research and Development Clinical Trials 119

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions.[1]. For example, most statin drugs can cause memory issues, muscle pain, fatigue and muscle weakness.

CBD 52

CBD THC Conditions Medicine 52

Project CBD

MAY 3, 2023

She is the medical director of Canna-Centers Wellness & Education and the clinical advisor to Cannformatics. She is also the author of Cannabis is Medicine: How Medical Cannabis and CBD are Healing Everything from Anxiety to Chronic Pain. But we may be on the cusp of having those trials, which would be very exciting.

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Cannabis Law Report

NOVEMBER 10, 2021

The NIH has also engaged a firm to manufacture Leu-enkephalin (L-ENK), the active ingredient in Envelta and a firm to manufacture the Molecular Envelope Technology (MET) that is used to carry the L-ENK to the brain to promptly suppress pain. In October 2021, Virpax announced that a $1.87 Christopher M. Chipman, CPA. Chief Financial Officer.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Cannabis Law Report

OCTOBER 6, 2021

With the additional funding recently secured by Virpax and the strengthening of our balance sheet, we are continuing to advance our product candidates and to move them through preclinical studies and into human clinical trials,” said Anthony Mack, Chairman and Chief Executive Officer of Virpax Pharmaceuticals. Christopher M.

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Cannabis Law Report

NOVEMBER 18, 2021

Nadav Kidron, Oramed CEO and Oravax Chairman, and Rodrigo Herrera, Genomma Lab Chairman, will hold a joint press event today, Thursday, November 18, 2021 at 11:00 am EST. The live press event will be available via Zoom. Oravax is also preparing to commence clinical trials in Israel.”. 19 vaccine candidate in Mexico.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Chronic Pain 52

Cannabis Law Report

NOVEMBER 15, 2021

Our lead product candidate is Envelta™, which utilizes MET to deliver enkephalin nanoparticles for acute and chronic pain including pain associated with cancer. Probudur™ is a single injection long-acting liposomal bupivacaine formulation being developed to manage post-operative pain.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

AUGUST 2, 2021

Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and Chronic Pain. Key findings from the pre-clinical trial are as follows: SCI-160 significantly alleviates pain up to 6 hours after injection as compared with vehicle-treated animals. TEL AVIV, Israel , Aug. Logo – [link].

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

DECEMBER 29, 2021

The company has received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in-human clinical trial and preparations to begin that trial are underway. Oravax is also preparing to commence clinical trials in Israel. Robert Schatz. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain CBD 52

Cannabis Law Report

OCTOBER 1, 2021

Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Christopher M. Chipman, CPA.

Research and Development 52

Research and Development Pharmaceutical Clinical Trials Chronic Pain 52

Cannabis Law Report

SEPTEMBER 20, 2021

Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Christopher M. Chipman, CPA.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

DECEMBER 28, 2021

Upon completion of all the required IND enabling studies and subsequent review by the FDA, Virpax intends to conduct a Phase 1 study to evaluate the relative bioavailability and pharmacokinetics of Epoladerm™ Virpax recently announced the execution of a clinical trial agreement with Altasciences Company, Inc.,

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52